Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing

Cogent Biosciences, Inc. COGT.O:

Cogent Biosciences enters commercial supply agreement with Hovione on Sept. 1, 2026 - SEC filing

Cogent Biosciences to purchase minimum percentages of bezuclastinib products from Hovione - SEC filing

Agreement effective for five-year term with automatic two-year renewals - SEC filing